Consultation with competitor companies

Companies marketing competitor products referred to within certain sections of the SMC Detailed Advice Document (DAD) have the opportunity to comment on the factual accuracy of what is said about their product.

A competitor product may be any patented medicine or non-medicinal treatment available in the UK, which reflects current management of the condition covered by the DAD (irrespective of whether the competitor medicine has previously been accepted for use by SMC). For the purposes of consultation with the marketing authorisation holder, a competitor product may be a licensed or off-label alternative to the medicine under review within the DAD.

The marketing authorisation holder of the competitor product will be consulted, in confidence, after the SMC decision has been communicated to NHSScotland, but prior to publication on the SMC website. They will be sent the full SMC DAD and invited to comment on the factual accuracy of information in relation to their product, contained in the Summaries of Comparative Efficacy, Safety and Clinical Effectiveness only of the DAD. Comments will be reviewed by the SMC Executive and both the submitting company and competitor company notified of any resultant change(s) to the DAD.

Where a competitor product is specifically referred to in the Summary of Comparative Health Economic Evidence or Value for Money section of the DAD, the competitor company will be forwarded a copy of the DAD, for information only.

Data that are commercial in confidence or academic in confidence will be removed prior to consulting with competitor companies.